The effects of cognitive-behavioral therapy on methamphetamine use

Phase 3

Conditions: Substance use.
Mental and behavioural disorders due to psychoactive substance use
F10-F19

Registration Number: IRCT2015091424012N1

Lead Sponsor: ational Drug and Alcohol Research Centre (NDARC), University of New South Wales

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: Female

Target Recruitment: 120

Inclusion Criteria

be aged between 18 and 60 years old; report regular methamphetamine use (score of at least 0.14 in OTI methamphetamine section); meet DSM.IV-TR criteria for heroin dependence before entry to MMT; using any route of methamphetamine such as smoking, injection and/or sniffing; be willing to provide urine specimens; be able to attend appointments throughout the trial; be in MMT for at least three months prior to recruitment.
Exclusion criteria: report a known concurrent severe medical and/or psychiatric conditions preventing giving informed consent; report social, medical, and/or psychiatric conditions that prevent them from attending the trial or require incarceration or hospitalization during the trial period; report withdrawal and/or intoxication symptoms at the time of recruitment; have received any similar CBT related to heroin and/or methamphetamine use within the past 12 months prior to intake.

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Methamphetamine use. Timepoint: 4 weeks following the end of intervention and a 3 month follow-up. Method of measurement: Opiate Treatment Index and Timeline Followback.;Severity of methamphetamine dependence. Timepoint: 4 weeks following the end of intervention and a 3 month follow-up. Method of measurement: Severity of Dependence Scale.;Stage of change for methamphetamine use. Timepoint: 4 weeks following the end of intervention and a 3 month follow-up. Method of measurement: Speed Use Ladder Questionnaire.;General Health. Timepoint: 4 weeks following the end of intervention and a 3 month follow-up. Method of measurement: General Health Questionnaire-28.

Secondary Outcome Measures

Name	Time	Method
Benzodiazepine use. Timepoint: 4 weeks following end of intervention and a 3-month follow-up. Method of measurement: Opiate Treatment Index.;Heroin use. Timepoint: 4 weeks following end of intervention and a 3-month follow-up. Method of measurement: Opiate Treatment Index.